Abstract
Introduction
With a considerable patient population and continued government focus on
lowering national smoking rates, the nicotine dependence market represents a
lucrative opportunity for pharmaceutical companies. With strong uptake since
launch in 2006 of Pfizer' s Chantix (varenicline), the seven major prescription
nicotine dependence market was estimated to total $1.35 billion in 2008.
Scope of this research
- Patient potential analysis across the seven major markets, Brazil, Russia,
India, and China as well as assessment of clinical unmet needs.
- Analysis of the prescription and over-the-counter pharmaceutical markets
for anti-smoking products from 20042008 in the seven major regions.
- Case study review of Chantix including historic sales data analysis,
opinion leader view on its safety and prospects, with scenario forecasts to
2018.
- In depth pipeline analysis, with detailed profiles of late-stage nicotine
vaccines that feed into a region-specific market projection to 2018.
Research and analysis highlights
Although US and UK smoking rates have fallen over the past decade, demand for
effective anti-smoking methods remains a significant requirement.
Additionally, with higher smoking rates and evolving government antismoking
initiatives, the substantial smoking populations in China, India and Russia
represent a real market opportunity.
Datamonitor anticipates Pfizer to be successful in reinstating prescriber and
patient confidence in Chantix by establishing a favorable risk-benefit ratio
and emphasizing the requirement for improved patient screening and follow-up.
Under this assumption, sales of Chantix are forecast to return to growth.
Through the late-stage development of Nabi' s NicVAX and Novartis and Cytos' s
NIC-002, nicotine vaccines remain a key focus of the nicotine dependence
pipeline. With the first major market launch predicted for 2012, Datamonitor
forecasts the two vaccines to generate strong annual revenues by 2018.
Key reasons to purchase this research
- Appreciate the nicotine dependence patient potential and where future
geographical market opportunities exist.
- Benchmark key late-stage pipeline nicotine dependence projects against
current market leading brands, supported by insight from key opinion leaders.
- Quantify the future market landscape with sales forecasts of marketed,
generics, and key late-stage pipeline drugs to 2018 in the US, 5EU and Japan.
| 
View Cart
